| Market Cap | 255.51K | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
| Income | -1.21M | Forward P/E | - | EPS next Y | - | 50D Avg Chg | -16.00% |
| Sales | 230.07k | PEG | - | EPS past 5Y | - | 200D Avg Chg | -99.00% |
| Dividend | N/A | Price/Book | N/A | EPS next 5Y | - | 52W High Chg | -100.00% |
| Recommedations | - | Quick Ratio | 0.03 | Shares Outstanding | 31.11M | 52W Low Chg | 50.00% |
| Insider Own | - | ROA | -116.59% | Shares Float | 30.39M | Beta | 0.79 |
| Inst Own | 10.67% | ROE | - | Shares Shorted/Prior | -/- | Price | 0.02 |
| Gross Margin | 100.00% | Profit Margin | - | Avg. Volume | 433,051 | Target Price | - |
| Oper. Margin | -300.82% | Earnings Date | Nov 27 | Volume | 62,210 | Change | -6.25% |
CNBX Pharmaceuticals Inc., a clinical stage company, engages in the discovery, development, and commercialization of novel cannabinoid-based products and technologies for the treatment of cancer. Its lead product candidate is Cannabics SR, an oral capsule developed for the treatment of patients with advanced cancer and cancer anorexia cachexia syndrome. The company is also developing various drug candidates, including PLP-33 for the treatment of lateral spreading or sessile, and colorectal polyps during colonoscopy; BRST-33 to treat breast cancer; MLN-33 for the treatment of Melanoma; and PRST-33 to treat prostate cancer. In addition, it is developing RCC-33, an oral capsule containing a formulation of cannabinoids for the treatment of colorectal cancer; and Cannabics CDx, an ex-vivo drug sensitivity test. The company was formerly known as Cannabics Pharmaceuticals Inc. and changed its name to CNBX Pharmaceuticals Inc. in March 2022. CNBX Pharmaceuticals Inc. was incorporated in 2004 and is based in Bethesda, Maryland.
